BIO vs CAH · rev $651.0M vs P/E 35, rev $254.25B
BIO (BIO) versus Cardinal Health Inc (CAH) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Cardinal Health Inc (CAH) is a medical distribution company listed on NYSE.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
Latest reported CAH revenue for 2026-06-30 was $254.25B. Net income was $1.71B. Revenue was up 14.2% from 2025-06-30 to 2026-06-30. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
BIO currently screens at market cap $0. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
Not investment advice. Open the BIO and CAH stock pages for the full models.
Not investment advice.